Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC277608 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 1332 |
0.1-0.2 | 22430 |
0.2-0.3 | 4286 |
0.3-0.4 | 1740 |
0.4-0.5 | 895 |
0.5-0.6 | 187 |
0.6-0.7 | 14 |
0.7-0.8 | 0 |
0.8-0.85 | 2 |
0.85-0.9 | 1 |
0.9-0.95 | 0 |
0.95-1 | 2 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC277608 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 291 |
0.1-0.2 | 1812 |
0.2-0.3 | 3440 |
0.3-0.4 | 2338 |
0.4-0.5 | 1075 |
0.5-0.6 | 179 |
0.6-0.7 | 25 |
0.7-0.8 | 1 |
0.8-0.85 | 0 |
0.85-0.9 | 0 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.7273 |
Intermediate Similarity |
NPD9472 |
Phase 3 |
0.679 |
Remote Similarity |
NPD9394 |
Clinical (unspecified phase) |
0.6759 |
Remote Similarity |
NPD9099 |
Clinical (unspecified phase) |
0.6759 |
Remote Similarity |
NPD9098 |
Phase 3 |
0.6609 |
Remote Similarity |
NPD9392 |
Approved |
0.6609 |
Remote Similarity |
NPD9396 |
Approved |
0.6585 |
Remote Similarity |
NPD715 |
Phase 3 |
0.6566 |
Remote Similarity |
NPD8835 |
Approved |
0.6387 |
Remote Similarity |
NPD9598 |
Discontinued |
0.6311 |
Remote Similarity |
NPD9101 |
Discontinued |
0.624 |
Remote Similarity |
NPD9305 |
Clinical (unspecified phase) |
0.623 |
Remote Similarity |
NPD9357 |
Approved |
0.6183 |
Remote Similarity |
NPD174 |
Discontinued |
0.6174 |
Remote Similarity |
NPD4824 |
Approved |
0.6174 |
Remote Similarity |
NPD4823 |
Approved |
0.616 |
Remote Similarity |
NPD1095 |
Clinical (unspecified phase) |
0.6147 |
Remote Similarity |
NPD8861 |
Approved |
0.6147 |
Remote Similarity |
NPD8859 |
Approved |
0.6147 |
Remote Similarity |
NPD8862 |
Approved |
0.6129 |
Remote Similarity |
NPD9583 |
Approved |
0.608 |
Remote Similarity |
NPD2119 |
Approved |
0.608 |
Remote Similarity |
NPD2118 |
Approved |
0.6017 |
Remote Similarity |
NPD269 |
Clinical (unspecified phase) |
0.6016 |
Remote Similarity |
NPD803 |
Phase 1 |
0.6016 |
Remote Similarity |
NPD809 |
Discontinued |
0.6 |
Remote Similarity |
NPD1918 |
Clinical (unspecified phase) |
0.5984 |
Remote Similarity |
NPD271 |
Approved |
0.5984 |
Remote Similarity |
NPD270 |
Clinical (unspecified phase) |
0.5984 |
Remote Similarity |
NPD268 |
Approved |
0.5952 |
Remote Similarity |
NPD991 |
Phase 2 |
0.5952 |
Remote Similarity |
NPD992 |
Clinical (unspecified phase) |
0.5938 |
Remote Similarity |
NPD3476 |
Approved |
0.5938 |
Remote Similarity |
NPD3475 |
Approved |
0.592 |
Remote Similarity |
NPD1807 |
Clinical (unspecified phase) |
0.5897 |
Remote Similarity |
NPD757 |
Phase 3 |
0.5802 |
Remote Similarity |
NPD3944 |
Approved |
0.5802 |
Remote Similarity |
NPD3942 |
Approved |
0.5802 |
Remote Similarity |
NPD4030 |
Approved |
0.5802 |
Remote Similarity |
NPD4029 |
Approved |
0.5802 |
Remote Similarity |
NPD4028 |
Approved |
0.5776 |
Remote Similarity |
NPD9082 |
Approved |
0.5726 |
Remote Similarity |
NPD1390 |
Phase 1 |
0.5726 |
Remote Similarity |
NPD1389 |
Clinical (unspecified phase) |
0.5726 |
Remote Similarity |
NPD1388 |
Phase 1 |
0.5714 |
Remote Similarity |
NPD3576 |
Approved |
0.5714 |
Remote Similarity |
NPD3575 |
Approved |
0.5714 |
Remote Similarity |
NPD9132 |
Discontinued |
0.568 |
Remote Similarity |
NPD5787 |
Discontinued |
0.5645 |
Remote Similarity |
NPD4811 |
Discontinued |
0.5643
|
Remote Similarity |
NPD1661 |
Suspended |